Fibronostics Expands U.S. Operations with Acquisition of Stone Clinical Laboratories

Fibronostics has successfully completed its acquisition of Stone Clinical Laboratories, a prominent provider of advanced laboratory services in the United States. This strategic move, announced on October 27, 2025, enhances Fibronostics’ capabilities in non-invasive diagnostics for metabolic and liver diseases, particularly in relation to metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD).

The acquisition comes at a critical juncture for the industry, marked by significant advancements such as the recent FDA approvals of therapeutic options like Madrigal Pharmaceuticals’ Rezdiffra and Novo Nordisk’s Wegovy. These developments indicate a growing investment in MASH and MASLD therapeutics and underscore the increasing demand for reliable diagnostics that can detect these conditions earlier and facilitate monitoring of treatment efficacy.

Strengthening Operations and Innovation

According to Brock Smith, Chief Executive Officer of Fibronostics, the addition of Stone Clinical Laboratories significantly bolsters the company’s U.S. laboratory infrastructure and operational expertise. This enhancement is expected to accelerate innovation in non-invasive diagnostics while fostering collaborations with partners in pharmaceuticals and healthcare to address the rising global burden of MASH and MASLD.

The expertise and testing capabilities of Stone Clinical Laboratories are anticipated to complement Fibronostics’ proprietary digital health platforms, including its flagship product, LIVERFASt. This partnership aims to advance biomarker development, research and development programs, and clinical validation studies, all of which are crucial for supporting therapeutic innovation and improving patient management.

Looking Ahead: The Future of Liver Care

As the landscape of liver treatment evolves, Smith emphasized the importance of precise and accessible diagnostics. “Therapeutic breakthroughs in MASH and MASLD are reshaping liver care,” he stated. “This acquisition positions Fibronostics to lead in providing scalable solutions that effectively bridge diagnostics and therapeutics.”

This acquisition represents a pivotal step in Fibronostics’ growth strategy. The combined resources and expertise of both organizations are expected to facilitate collaborations with biopharmaceutical innovators, healthcare systems, and payers, ultimately enhancing early detection and improving health outcomes for patients globally.

Fibronostics is recognized as a global health technology company specializing in non-invasive diagnostic solutions for chronic diseases, particularly liver and metabolic disorders. Its innovative platform, LIVERFASt, allows clinicians to swiftly and accurately assess liver health at scale. By partnering with pharmaceutical firms, diagnostic laboratories, and healthcare systems, Fibronostics aims to advance next-generation liver diagnostics and ensure better patient outcomes worldwide.

For further information, interested parties can contact Brock Smith, CEO of Fibronostics, at +1-888-552-1603 or via email at [email protected].